Secretin-enhanced Magnetic Resonance Imaging (S-MRI) for Pancreatic Cancer Detection

Key facts

Sponsor

Elizabeth Hecht

Principal Investigator

Elizabeth Hecht, MD

Columbia University

Intervention

Secretin(drug)

Eligibility

18-75 years · All sexes

Timeline

2010 – 2013

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Intraductal papillary mucinous carcinoma of pancreas

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT07216521
  Intent of Surgery for IPMN
  NYU Langone Health
• RECRUITINGNCT07117045
  Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer
  Changhai Hospital
• RECRUITINGNCT06574373
  Identification of New Theranostic Biomarkers of Pancreatic Tumor Progression
  Fondazione Policlinico Universitario Agostino Gemelli IRCCS
• ACTIVE NOT RECRUITINGNANCT06712797
  Physical Activity and Nutrition to Halt Elevated Risk in the Pancreas Interception Center
  H. Lee Moffitt Cancer Center and Research Institute
• RECRUITINGNCT06694792
  Integration of Multiomics Markers for Invasive IPMNs Identification Through the Set-up of the INvasive Cyst bIomarkers Detection (INCITE) Consortium
  IRCCS San Raffaele
• ENROLLING BY INVITATIONNCT06276764
  The LINFU® U.S. Registry in Patients With IPMN (Intraductal Papillary Mucinous Neoplasm of the Pancreas)
  Adenocyte, LLC
• RECRUITINGNCT06638866
  AI-powered Early Detection for Pancreatic Cancer Via Non-contrast CT in Opportunistic Screening Cohort
  Changhai Hospital
• ACTIVE NOT RECRUITINGPHASE2NCT06519097
  Study of IPMN Progression Prevention With Tocotrienol (SIPP-T3)
  H. Lee Moffitt Cancer Center and Research Institute

See all trials for Intraductal papillary mucinous carcinoma of pancreas →